Michelle McMurry-Heath, BIO CEO (BIO via YouTube)

BIO looks to re­struc­ture, lay­ing off staff amid chal­lenge to the trade org's nor­mal face-to-face style

The bio­phar­ma in­dus­try, on the whole, had a red-let­ter year in 2020 amid Covid-19, with fundrais­ing at an all-time high and ma­jor play­ers speed­ing vac­cines ahead to ap­proval. But for BIO, the in­dus­try’s lead­ing trade or­ga­ni­za­tion, the pan­dem­ic has prompt­ed a re­con­sid­er­a­tion of the game plan.

BIO will piv­ot to dig­i­tal as the Covid-19 pan­dem­ic con­tin­ues to rage, mak­ing “some staff re­duc­tions” as it looks to bring its rough­ly 37,000 in-per­son meet­ings each year to the web, the or­ga­ni­za­tion said Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.